This review argues that women’s higher Alzheimer disease risk may be shaped in part by midlife neuroendocrine aging, especially the menopause transition, rather than by longevity alone. It highlights early menopause, bilateral oophorectomy, vasomotor symptoms, and midlife cognitive changes as underinvestigated but potentially important risk markers, while calling for sex-specific, biomarker-driven prevention strategies.